Abstract
Purpose The purpose of this study is to report the genetic findings of a large heterogeneous patient population (n=551) with the clinical diagnosis of Familial Exudative Vitreoretinopathy (FEVR).
Methods Patients (n=486) were clinically diagnosed with FEVR by exam, birth history, family history, and wide-field fluorescein angiography (WFA). Patients were excluded if WFA was not performed to confirm a proper diagnosis. DNA samples were prospectively collected and analyzed for gene mutations associated with FEVR. The patients represent a heterogenous population: 40% Michigan residents; 48% U.S. residents (non-Michigan); 12% non-U.S. residents. Specifically, alterations in NDP, FZD4, LRP5, TSPAN12, ZNF408, CTNNB1, KIF11 were evaluated.
Results The majority of FEVR patients (69%) had an identifiable gene mutation, with 55% of mutations affecting traditional Wnt-signaling genes: NDP 13%; FZD4 11%; LRP5 25%; TSPAN12 6%. Other affected genes represented 14% of mutations, with ZNF408 accounting for 9%.
Conclusions FEVR remains a clinical diagnosis with WFA necessary for making the diagnosis of FEVR. This database demonstrated that, with proper diagnosis, the majority of patients have a definable genetic alteration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
wcg IRB of Associated Retinal Consultants gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
